This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neu...
Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.
Commercial arrangement
There is a simple discount patient access scheme for regorafenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS or...
Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Commercial arrangement
There is a commercial arrangement for nivolumab. NHS organisations can get...
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.
Commercial arrangement
There is a managed access agreement, which includes a patient access scheme, for trastuzumab derux...
Next
Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.
Commercial arrangement
There is a commercial access agreement for nivolumab...
Non-small cell lung cancer (NSCLC) is a heterogeneous disease accounting for approximately 85% of all lung cancers. Only 17% of patients are diagnosed at an early stage. Treatment is multidisciplinary and radiotherapy plays a key role in all stages of the disease. More than 50% of patients with NSCLC are...
This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or
brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including
standardising the care people have, how information and support are provided, and palliative care.
In January 2021, we...
Fassnacht, M;
Dekkers, OM;
Else, T;
Baudin, E;
Berruti, A;
de Krijger, R;
Haak, HR;
Mihai, R;
Assie, G;
Terzolo, M.
Adrenocortical carcinoma (ACC) is a rare and in most cases steroid hormone-producing tumor with variable prognosis. The purpose of these guidelines is to provide clinicians with best possible evidence-based recommendations for clinical management of patients with ACC based on the GRADE (Grading of Recomm...
Adrenal Cortex Neoplasms,
Neoplasm Metastasis,
Antineoplastic Agents, Hormonal/therapeutic use,
Etoposide/administration & dosage,
Mitotane/therapeutic use,
Doxorubicin/therapeutic use,
Adrenocortical Carcinoma/diagnosis,
Adrenocortical Carcinoma,
Adrenocortical Carcinoma/drug therapy,
Radiotherapy,
Cisplatin/therapeutic use,
Antineoplastic Combined Chemotherapy Protocols/therapeutic use,
Catheter Ablation,
Adrenalectomy,
Adrenal Cortex Neoplasms/therapy,
Adrenocortical Carcinoma/therapy,
Chemoembolization, Therapeutic
This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care....
This quick guide contains the key recommendations from the national clinical guideline for the treatment of brain metastases. The national clinical guideline for the treatment of brain metastases focuses on treatment, including clarification of the treatment modality to be used in each individual case. B...
